(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents.
A series of 3-[(2,4-dioxothiazolidin-5-yl)methyl]benzamide derivatives was prepared as part of a search for antidiabetic agents. A structure-activity relationship study of these compounds led to the identification of 5-[(2,4-dioxothiazolidin-5-yl)methyl]-2-methoxy-N-[[4-(trifluorome thyl)-phenyl]methyl]benzamide (KRP-297) as a candidate drug for the treatment of diabetes mellitus.
Nomura
M
M
Central Research Laboratories, Kyorin Pharmaceutical Co., Ltd., Tochigi, Japan.
Kinoshita
S
S
Satoh
H
H
Maeda
T
T
Murakami
K
K
Tsunoda
M
M
Miyachi
H
H
Awano
K
K
D000818:Animals; D001786:Blood Glucose / Q000032:analysis; D007004:Hypoglycemic Agents / Q000737:chemistry* / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D051379:Mice; D008820:Mice, Obese; D000077205:Pioglitazone; D013329:Structure-Activity Relationship; D013844:Thiazoles / Q000737:chemistry* / Q000494:pharmacology*; D045162:Thiazolidinediones; D053778:Thiazolidines; D014280:Triglycerides / Q000097:blood
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013844:Thiazoles; D045162:Thiazolidinediones; D053778:Thiazolidines; D014280:Triglycerides; C116017:5-((2,4-dioxo-5-thiazolidinyl)methyl)-2-methoxy-N-((4-(trifluoromethyl)phenyl)methyl)benzamide; D000077205:Pioglitazone